Imperial College London

DrAbbasDehghan

Faculty of MedicineSchool of Public Health

Reader in Cardiometabolic Disease Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3347a.dehghan CV

 
 
//

Location

 

157Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{van:2016:10.1186/s12933-016-0387-4,
author = {van, Herpt TT and Dehghan, A and van, Hoek M and Ikram, MA and Hofman, A and Sijbrands, EJ and Franco, OH},
doi = {10.1186/s12933-016-0387-4},
journal = {Cardiovasc Diabetol},
pages = {69--69},
title = {The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study.},
url = {http://dx.doi.org/10.1186/s12933-016-0387-4},
volume = {15},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: To evaluate the clinical value of metabolic syndrome based on different definitions [American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), International Diabetes Federation (IDF) and European Group for the Study of Insulin Resistance (EGIR)] in middle-aged and elderly populations. METHODS: We studied 8643 participants from the Rotterdam study (1990-2012; mean age 62.7; 57.6 % female), a large prospective population-based study with predominantly elderly participants. We performed cox-proportional hazards models for different definitions, triads within definitions and each separate component for the risk of incident type 2 diabetes mellitus, coronary heart disease, stroke, cardiovascular- and all-cause mortality. RESULTS: In our population of 8643 subjects, metabolic syndrome was highly prevalent (prevalence between 19.4 and 42.4 %). Metabolic syndrome in general was associated with incident type 2 diabetes mellitus (median follow-up of 6.8 years, hazard ratios 3.13-3.78). The associations with coronary heart disease (median follow-up of 7.2 years, hazard ratios 1.08-1.32), stroke (median follow-up of 7.7 years, hazard ratios 0.98-1.32), cardiovascular mortality (median follow-up of 8.2 years, ratios 0.95-1.29) and all-cause mortality (median follow-up of 8.7 years, hazard ratios 1.05-1.10) were weaker. AHA/NHLBI- and IDF-definitions showed similar associations with clinical endpoints compared to the EGIR, which was only significantly associated with incident type 2 diabetes mellitus. All significant associations disappeared after correcting metabolic syndrome for its individual components. CONCLUSIONS: Large variability exists between and within definitions of the metabolic syndrome with respect to risk of clinical events and mortality. In a relatively old population the metabolic syndrome did not show an additional predictive value on top of its individual components. So, besides as a manner of easy identification of high risk
AU - van,Herpt TT
AU - Dehghan,A
AU - van,Hoek M
AU - Ikram,MA
AU - Hofman,A
AU - Sijbrands,EJ
AU - Franco,OH
DO - 10.1186/s12933-016-0387-4
EP - 69
PY - 2016///
SP - 69
TI - The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study.
T2 - Cardiovasc Diabetol
UR - http://dx.doi.org/10.1186/s12933-016-0387-4
UR - http://www.ncbi.nlm.nih.gov/pubmed/27117940
VL - 15
ER -